Efficacy and Safety of AJU-C52 in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 193 participants.

Also called NCT06416865

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 193 participants (enrolled count) (from the registry)
Sponsor
AJU Pharm Co., Ltd. (from the registry)
Registry
  • NCT NCT06416865
Other papers using this trial's data
  • Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial Journal of clinical hypertension (Greenwich, Conn.), 2026-09 DOI, PubMed 42723352, PMC13562912 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06416865. Randomized; quadruple masking; primary purpose treatment. Start 2022-10-18 (actual); primary completion 2024-12-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
Condition
Essential Hypertension
Intervention (Drug)
AJU-C52L, AJU-C52
Intervention (Drug)
C52R1L, C52R1M
Lead sponsor
AJU Pharm Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06416865
Content hash
b9a7d13ef6f379cf73999fa3da5a8278acac4412ff920a4941495e635dce5a7f